Septerna Inc

SEPN remains in a Stage 2 uptrend but is consolidating between its 9/20 EMAs and the 50-day SMA. Short-term momentum is neutral, and price is holding above the rising 50-day SMA. A disciplined pullback entry into support is preferred, awaiting clear re-acceleration above the 20-day EMA before committing.

• ↑Unanimous buy consensus across 10 analysts; $45.00 avg. target (+27.9%)
• ↑SEP-479 preclinical results show promising PTH1R agonist progress
• ↓Q2 EPS forecast at -$0.426; Q1 EPS exceeded estimates at -$0.19